Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Benoit BlanchetAlexandre Xu-VuilardAnne JouinotFlorent PuissetDavid CombarelOlivier HuillardFélicien Le LouedecFabienne ThomasMarcus TeixeiraRonan FlippotLoic MoureyLaurence AlbigesThomas PudlarzCharlotte JolyChristophe TournigandJonathan ChauvinAlicja PuszkielEtienne ChatelutXavier DeclevesMichel VidalFrançois GoldwasserStéphane OudardJacques MedioniYann-Alexandre Vano

Published in: British journal of cancer (2024)

Early plasma drug monitoring may be useful to optimise cabozantinib treatment in mRCC patients treated in monotherapy, especially in frail patients starting at a lower than standard dose.

Keyphrases

metastatic renal cell carcinoma
end stage renal disease
newly diagnosed
healthcare
ejection fraction
chronic kidney disease
palliative care
combination therapy
prognostic factors
peritoneal dialysis
quality improvement
randomized controlled trial
clinical practice
clinical trial
pain management
patient reported